Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab in Stage I Solid/Micropapillary Lung Adenocarcinoma
NCT03254004Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in lung adenocarcinoma, sponsored by Samsung Medical Center. Primary endpoint: Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03254004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254004.